Article Text

Download PDFPDF

#1082 Endometrial mixed epithelial carcinoma: epidemiology, treatment and survival – a 10-year retrospective cohort study from a single institution
  1. Christina Pappa1,
  2. Valentina Le Thanh1,
  3. Sarah Louise Smyth1,
  4. Andreas Zouridis1,
  5. Joshua Rencher2,
  6. Negin Sadeghi1,
  7. Ammara Kashif1,
  8. Kianoush Zarrindej3,
  9. Alisha Sattar1,
  10. Stephen Damato1,
  11. Mostafa Abdalla4,
  12. Sean Kehoe1,
  13. Susan Addley5 and
  14. Hooman Soleymani Majd1
  1. 1Oxford University Hospitals, NHS Foundation Trust, Oxford, UK
  2. 2Royal Berkshire NHS Foundation Trust, Reading, UK
  3. 3Buckinghamshire NHS Foundation Trust, Bucks, UK
  4. 4Guy’s and St Thomas’ NHS Foundation Trust, London, UK
  5. 5University Hospitals of Derby and Burton NHS Foundation Trust, Derby, UK


Introduction/Background Mixed endometrial carcinoma refers to rare endometrial tumours that are comprised of two or more distinct histotypes, at least one of which is serous or clear cell. Limited data is available on the recurrence rates for mixed epithelial endometrial carcinoma, as it comrises a relatively understudied subtype of endometrial cancer. The aim of this study is to evaluate the epidemiology, treatment outcomes and survival rates of patients with mixed endometrial carcinoma.

Methodology Medical records of the patients diagnosed with mixed endometrial carcinoma between March 2010 and January 2020 reviewed retrospectively. Clinicopathological variables and treatment strategies were assessed, and overall survival (OS) and disease-free survival (DFS) rates were evaluated.

Results A total of 34 patients were included in the study. Histology of endometrioid and serous component was found in 26 (76.5%) patients, followed by serous and clear cell components (5/354 14.5%) and a mixture of endometrioid, serous and clear cell components (3/34, 8.8%). The median age was 70 years (range 52–84), and median follow-up time was 55 months. Most patients (70%) were treated with laparoscopy. Overall, the 5-year disease-free survival rate (DFS) and the 5-year overall survival (OS) rate was 50.4% and 52.4%, respectively. Advanced disease stage was found to be independently correlated with worse 5-year disease-free survival (DFS) and overall survival (OS) rates (p<0.001).

Conclusion The management of mixed epithelial endometrial carcinoma presents several challenges for clinicians and researchers that need to be addressed to improve oncologic outcomes. Accurate and early diagnosis plays a fundamental role to determine the appropriate treatment plan. Improved diagnostic techniques, such as molecular profiling and imaging technologies, as well as identification of specific biomarkers associated with the distinct features of the tumour, can help clinicians effectively stratify the patients and tailor treatment accordingly. Undoubtedly, the implementation of molecular analysis will offer further diagnostic and management insights.

Disclosures no

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.